These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Concurrent BRAFV600E and BRCA Mutations in MSS Metastatic Colorectal Cancer: Prevalence and Case Series of mCRC patients with prolonged OS. Cannon TL; Randall JN; Sokol ES; Alexander SM; Wadlow RC; Winer AA; Barnett DM; Rayes DL; Nimeiri HS; McGregor KA Cancer Treat Res Commun; 2022; 32():100569. PubMed ID: 35567913 [TBL] [Abstract][Full Text] [Related]
5. Association of RNF43 Genetic Alterations With BRAF Vogel A; Murugesan K; Kendre G; Quintanilha JCF; Ross JS; Brummer T; Saborowski A JCO Precis Oncol; 2024 Feb; 8():e2300411. PubMed ID: 38394466 [TBL] [Abstract][Full Text] [Related]
6. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy? Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431 [TBL] [Abstract][Full Text] [Related]
7. RNF43 mutation is associated with aggressive tumor biology along with BRAF V600E mutation in right-sided colorectal cancer. Matsumoto A; Shimada Y; Nakano M; Oyanagi H; Tajima Y; Nakano M; Kameyama H; Hirose Y; Ichikawa H; Nagahashi M; Nogami H; Maruyama S; Takii Y; Ling Y; Okuda S; Wakai T Oncol Rep; 2020 Jun; 43(6):1853-1862. PubMed ID: 32236609 [TBL] [Abstract][Full Text] [Related]
8. Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF García-Alfonso P; Lièvre A; Loupakis F; Tadmouri A; Khan S; Barcena L; Stintzing S Crit Rev Oncol Hematol; 2022 May; 173():103646. PubMed ID: 35344913 [TBL] [Abstract][Full Text] [Related]
9. Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States. Trunk A; Braithwaite M; Nevala-Plagemann C; Pappas L; Haaland B; Garrido-Laguna I J Natl Compr Canc Netw; 2022 Feb; 20(2):144-150. PubMed ID: 35130499 [TBL] [Abstract][Full Text] [Related]
10. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments. Ros J; Matito J; Villacampa G; Comas R; Garcia A; Martini G; Baraibar I; Saoudi N; Salvà F; Martin Á; Antista M; Toledo R; Martinelli E; Pietrantonio F; Boccaccino A; Cremolini C; Dientsmann R; Tabernero J; Vivancos A; Elez E Ann Oncol; 2023 Jun; 34(6):543-552. PubMed ID: 36921693 [TBL] [Abstract][Full Text] [Related]
11. DNA Mutational Profiling in Patients With Colorectal Cancer Treated With Standard of Care Reveals Differences in Outcome and Racial Distribution of Mutations. Innocenti F; Mu W; Qu X; Ou FS; Kabbarah O; Blanke CD; Venook AP; Lenz HJ; Rashid NU J Clin Oncol; 2024 Feb; 42(4):399-409. PubMed ID: 37992266 [TBL] [Abstract][Full Text] [Related]
12. Treatment of patients with BRAF Germani MM; Vetere G; Santamaria F; Intini R; Ghelardi F; Bensi M; Boccaccino A; Minelli A; Carullo M; Ciracì P; Passardi A; Santucci S; Giampieri R; Persano M; Fenocchio E; Puccini A; Lonardi S; Pietrantonio F; Salvatore L; Cremolini C ESMO Open; 2024 Apr; 9(4):102996. PubMed ID: 38613911 [TBL] [Abstract][Full Text] [Related]
14. Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. Kayhanian H; Goode E; Sclafani F; Ang JE; Gerlinger M; Gonzalez de Castro D; Shepherd S; Peckitt C; Rao S; Watkins D; Chau I; Cunningham D; Starling N Clin Colorectal Cancer; 2018 Mar; 17(1):e69-e76. PubMed ID: 29129559 [TBL] [Abstract][Full Text] [Related]
15. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study. Shinozaki E; Yoshino T; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Mimaki S; Nakai C; Matsushima K; Suzuki Y; Akagi K; Yamanaka T; Nomura S; Fujii S; Esumi H; Sugiyama M; Nishida N; Mizokami M; Koh Y; Abe Y; Ohtsu A; Tsuchihara K Br J Cancer; 2017 Nov; 117(10):1450-1458. PubMed ID: 28972961 [TBL] [Abstract][Full Text] [Related]
16. RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer. Schrock AB; Lee JK; Sandhu J; Madison R; Cho-Phan C; Snider JW; Castellanos E; Venstrom JM; Fakih M Oncologist; 2021 Jun; 26(6):469-475. PubMed ID: 33465286 [TBL] [Abstract][Full Text] [Related]
17. Treatment of Ros J; Rodríguez-Castells M; Saoudi N; Baraibar I; Salva F; Tabernero J; Élez E Expert Rev Anticancer Ther; 2023; 23(8):797-806. PubMed ID: 37482749 [TBL] [Abstract][Full Text] [Related]
18. Effect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain. Martínez-Lago N; Fernández-Montes A; Covela M; Brozos EM; De la Cámara J; Méndez Méndez JC; Jorge-Fernández M; Cousillas Castiñeiras A; Reboredo C; Arias Ron D; Pellón Augusto ML; González Villarroel P; Graña B; Salgado Fernández M; Carral Maseda A; Vázquez Rivera F; Candamio Folgar S; Reboredo López M; BMC Cancer; 2021 Jan; 21(1):64. PubMed ID: 33446148 [TBL] [Abstract][Full Text] [Related]
19. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267 [TBL] [Abstract][Full Text] [Related]